ClinicalTrials.gg
CompletedNCT04373265Updated Feb 23, 2024

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

A Phase 1 interventional study of Relacorilant and Pembrolizumab in Adrenocortical Carcinoma, sponsored by Corcept Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Adrenocortical Carcinoma with a site in United States — 11 open to participants now, 18 under way, none of them phase 3. Adrenocortical Carcinoma · United States.

Enrollment
39th of 49
15 · median 40
Started
2020
with 3 others
Phase 1
20 of 56
5 open now
Registered
43rd of 56
by date
Lead sponsor
3 of 56
Corcept Therapeutics

Among the 56 studies in Adrenocortical Carcinoma with a site in United States, this one is the 39th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2020, is one of 20 in phase 1, and was the 43rd registered.

Adrenocortical Carcinoma

94 studies on the registry are indexed under Adrenocortical Carcinoma; 26 are open to participants now.

Browse Adrenocortical Carcinoma studies →

Open to participants now

11 of the 56 studies in Adrenocortical Carcinoma with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Adrenocortical Carcinoma studies recruiting now, 15 (71%) set no upper age limit and 2 (10%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Adrenocortical Carcinoma with a site in United States, or all of them as a file.
02

Study summary

This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).

Read the detailed description

Relacorilant is a small molecule antagonist of the glucocorticoid receptor (GR).

The goal of this study is to assess the safety and efficacy of relacorilant when given in combination with pembrolizumab in patients with advanced adrenocortical carcinoma (ACC) which produces too much stress hormone (cortisol). Too much stress hormone (cortisol) is also called glucocorticoid (GC) excess.

Eligible patients are those with advanced ACC that produces too much cortisol.

Patients will receive treatment until progressive disease (PD) (per RECIST v1.1) is confirmed, experience unmanageable toxicity, or until other treatment discontinuation criteria are met. All patients will be followed for documentation of disease progression, survival information (i.e., date and cause of death) and subsequent treatment.

03

Conditions studied

  • Adrenocortical Carcinoma

Keywords

  • Adrenocortical Carcinoma
  • Adrenal Carcinoma
  • Adrenal Autonomy
  • Excess Glucocorticoid
  • Hypertension
  • Hyperglycemia
  • Type 2 Diabetes
  • Impaired Glucose Tolerance
  • Cortisol
  • Cushing
  • Cushing syndrome
  • Hypercortisolemia
  • Cushingoid
  • Moon Face
  • Dorsocervical Fat Pad
  • Pembrolizumab
  • Glucocorticoid Receptor
  • Relacorilant
  • GR Antagonist
  • Adrenal Corticotropic Hormone (ACTH)
  • Adrenocortical Hyperfunction
  • Adrenal Gland Diseases
  • Endocrine System Diseases
  • Pathologic Processes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed ACC (advanced unresectable and/or )
  • based upon v1.1 as determined by the Investigator.
  • Documented GC excess (too much cortisol).
  • For patients who have received mitotane within 3 months prior to screening, mitotane levels must be \<4 mg/L at screening.
  • (ECOG) performance status ≤2.
  • Adequate organ and bone marrow function (determined through blood and urine tests)
  • Negative pregnancy test for patients of at the Screening and every 6 weeks (+ or - 7 days) in female patients of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 4 weeks prior to enrollment. If the participant underwent major surgery, they must have recovered adequately prior to starting study treatment.
  • Have received and responded (complete response [CR] or partial response [PR]) to prior treatment with any prior or any other agents targeting T-cell stimulation pathways
  • Taking a concomitant medication that is a strong Cytochrome P450 3A () inducer, or that is a substrate of CYP3A with a narrow therapeutic index
  • Known untreated parenchymal or have uncontrolled central nervous system (CNS) . Patients must not require and must be neurologically stable without corticosteroids for a minimum of 3 weeks prior to the commencement of the study. Patients with neurologic symptoms must undergo a CT/MRI to rule out occult CNS metastases.
  • Requirement for chronic systemic GC treatment, such as active disease requiring systemic treatment (corticosteroids or other medication)
  • Patients requiring inhaled glucocorticoids but have no other alternative treatment option if their condition deteriorates during the study.
  • toxicity from prior systemic cytotoxic therapies or radiotherapy that in the opinion of the Investigator has not resolved to v5.0 Grade 1 or less prior to the first dose of relacorilant.
  • Treated with the following prior to the first dose of relacorilant:

    1. Any product, systemic anticancer therapy, or radiation therapy within 21 days
    2. Antibodies or anticancer vaccines within 60 days
    3. Mifepristone or other GR antagonists within 5 half-lives of these medications
    4. Adrenostatic medications within 5 half-lives of these medications
  • History of severe to another monoclonal antibody
  • Other concurrent cancer or a history of another invasive within the last 3 years that has a likelihood of recurrence of >30% within the next 5 years. Adequately treated basal and squamous skin cancers, ductal carcinoma in situ, cervical cancer, prostate cancer, non-muscle invasive urothelial cancer or other tumors curatively treated with no evidence of disease are permissible.
  • (HIV) or current chronic/active infection with virus or virus including: Chronic or active hepatitis B as diagnosed by serologic tests. In equivocal cases, hepatitis B or C polymerase chain reaction may be performed and must be negative for enrollment.
  • Clinically significant uncontrolled condition(s) or a condition which, in the opinion of the Investigator, may confound the results of the trial or interfere with the patient's participation, including but not limited to:

    1. Unstable angina pectoris, angioplasty, cardiac stenting, or myocardial infarction 3 months before study entry.
    2. Active infection that requires parenteral antibiotics.
    3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Relacorilant in Combination with Pembrolizumab

    Participants will be treated on Day -3 to Day 1 (Cohort 1 under fasting conditions) or Day -6 to Day 1 (Cohort 2 under fed conditions) for Cycle 1 only. During the lead-in period, 300 mg relacorilant will be administered daily for 4 -7 days. Patients will receive their first pembrolizumab infusion on Cycle 1 Day 1. The participants will then receive combined treatment from Cycle 1 Day 1 until confirmed PD or unacceptable toxicity. Pembrolizumab will be administered every 6 weeks (on Day 1 of each 42-day cycle) and relacorilant will be administered daily. Optional Cohort 3 will lead-in with 400 mg relacorilant once daily for 7 days and combined treatment of relacorilant and pembrolizumab, depending on PD and toxicity.

    Drug: Relacorilant · Drug: Pembrolizumab

Interventions

  • Relacorilant, 100 mg soft gel capsules orally once daily

    Also known as: CORT125134

  • Pembrolizumab 400 mg infusion every 6 weeks

    Also known as: Keytruda

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity (DLT)

    Evaluate the percentage of patients with a dose-limiting toxicity

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Non-Progression Rate (NPR)

    Evaluate the non-progression rate (NPR) per RECIST v1.1

    Time frame: 24 weeks from enrollment

  2. Progression-Free Survival (PFS)

    Evaluate progression-free survival (PFS) per RECIST v1.1

    Time frame: From date of first treatment, until the date of first documented progression or date of death from any cause, whichever came first, up to month 24

  3. Number of Participants with Adverse Events

    Adverse events (AEs) by severity grade using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)

    Time frame: Up to 37 days post-treatment

  4. Plasma Concentrations of Relacorilant in Combination with Pembrolizumab in Patients with Advanced ACC and Glucocorticoid Excess

    Plasma concentrations of relacorilant in combination with pembrolizumab will be calculated in patients with advanced ACC and glucocorticoid excess

    Time frame: Up to 24 months

07

Study locations

6 sites
  • Site #150, Stanford Cancer Center
    Stanford, California 94305, United States
  • Site #007, Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Site #074, University of Michigan Medical School
    Ann Arbor, Michigan 48109, United States
  • Site #030 Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Site #051, Memorial Hospital
    New York, New York 10022, United States
  • Site #183, The University of Texas M.D. Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Oct 2023, 36 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2020
First posted
May 4, 2020
StartActual
Sep 30, 2020
Primary completionActual
Oct 17, 2023
CompletionActual
Jan 12, 2024
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04373265
Responsible party
Sponsor
First posted
May 4, 2020
Start date
Sep 30, 2020
Primary completion
Oct 17, 2023
Completion
Jan 12, 2024
Last update
Feb 23, 2024

Study contacts

Andreas G Moraitis, MD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relacorilant

Start the discussion